High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study

Pratibha Patil, et al. High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study. Int. J Med. Pharm. Res., 6 (5): 1529‐1536, 2025 1529 International Journal of Medical and Pharmaceutical Research Online ISSN-2958-3683 | Print ISSN-2958-3675 Frequency: Bi-Monthly Available online on: https://ijmpr.in/ Research Article High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study Pratibha Patil Department of Radiology, Noble hospitals ,Pune Maharashtra India A B S T R A C T Corresponding Author: Pratibha Patil Department of Radiology, Noble hospitals ,Pune Maharashtra India Received: 03-09-2025 Accepted: 30-09-2025 Available online: 17-10-2025 Background: Persistent respiratory symptoms after COVID-19 have raised concerns about post-infectious interstitial lung disease (ILD). High-resolution computed tomography (HRCT) is essential for evaluating such pulmonary sequelae. Aim: To assess HRCT findings in post-COVID patients with respiratory symptoms and determine the prevalence and severity of interstitial lung changes. Materials and Methods: This cross-sectional study included 50 post-COVID-19 patients at Noble Hospital, Pune, over one year. All patients had RT-PCR– confirmed COVID-19 and presented with respiratory symptoms ≥4 weeks postinfection. HRCT scans were evaluated for interstitial changes. Associations with clinical parameters were analyzed using SPSS (v26); p < 0.05 was considered significant. Results: Fibrotic changes were observed in 42% of patients. Common HRCT findings included ground-glass opacities (76%), interlobular septal thickening (58%), and reticulations (44%). Fibrosis was significantly associated with oxygen therapy during acute COVID-19 (p < 0.01), hospitalization status (p < 0.05), and duration since recovery (p < 0.05). Lower lobe predominance was noted in 84% of cases. HRCT severity scores showed moderate-to-severe involvement in 62% of patients. Conclusion: A substantial proportion of post-COVID patients show fibrotic lung changes on HRCT, especially those with severe disease or delayed recovery. HRCT is a valuable tool for early detection and monitoring of post-COVID interstitial lung disease. Copyright © International Journal of Medical and Pharmaceutical Research Keywords: Post-COVID fibrosis, Interstitial lung disease, HRCT chest, Ground-glass opacities, Pulmonary sequelae, COVID-19, Traction bronchiectasis. INTRODUCTION Coronavirus disease 2019 (COVID-19), caused by the SARS-CoV-2 virus, primarily affects the respiratory system. While most patients recover without significant long-term pulmonary complications, a subset of individuals, especially those with moderate to severe disease, may experience persistent respiratory symptoms due to post-COVID pulmonary sequelae [1,2]. Among these, interstitial lung disease (ILD) has emerged as a significant cause of morbidity in the postCOVID population [3]. High-resolution computed tomography (HRCT) has become the imaging modality of choice for detecting and evaluating interstitial lung involvement in both acute and chronic phases of COVID-19 infection [4]. HRCT provides detailed anatomical visualization of the pulmonary parenchyma, helping to identify features such as ground-glass opacities (GGOs), reticulations, traction bronchiectasis, honeycombing, and fibrotic changes that are characteristic of interstitial lung disease [5]. Post-COVID interstitial changes often resemble patterns of organizing pneumonia or fibrotic ILD, which may persist or progress even after clinical recovery [6,7]. The presence and extent of these changes are known to correlate with disease severity, need for oxygen therapy, and duration since infection [8,9]. Early identification of fibrotic patterns on HRCT can assist in timely intervention, rehabilitation, and long-term respiratory care [10]. Pratibha Patil, et al. High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study. Int. J Med. Pharm. Res., 6 (5): 1529‐1536, 2025 1530 Although several studies have addressed pulmonary fibrosis following COVID-19, limited Indian data exist specifically focusing on HRCT patterns and severity of ILD in the post-COVID phase [11,12]. This study was undertaken to evaluate the spectrum and severity of interstitial lung changes on HRCT in post-COVID patients presenting with persistent respiratory symptoms, and to analyze associations with clinical parameters such as prior hospitalization, oxygen requirement, comorbidities, and time since infection. MATERIALS AND METHODS Study Design and Setting This was a descriptive, cross-sectional observational study conducted over one year at the Department of Radiology, Noble Hospital, Pune. The study was carried out after obtaining approval from the Institutional Ethics Committee. Study Population The study included 50 post-COVID-19 patients who presented with persistent respiratory symptoms (such as breathlessness, cough, or chest discomfort) more than four weeks after the initial SARS-CoV-2 infection. All patients had a confirmed diagnosis of COVID-19 by RT-PCR. Inclusion Criteria • Patients aged ≥18 years. • History of laboratory-confirmed COVID-19 infection. • Persistent respiratory symptoms for ≥4 weeks post-infection. • Patients who underwent High-Resolution Computed Tomography (HRCT) of the chest for evaluation. • Patients who provided informed consent. Exclusion Criteria • Patients with pre-existing interstitial lung disease (ILD) diagnosed prior to COVID-19 infection. • Patients with active pulmonary tuberculosis, malignancy, or other chronic lung disorders unrelated to COVID19. • Incomplete clinical or imaging records. Data Collection Detailed clinical history, demographic data, comorbidities, and duration since COVID-19 recovery were recorded for each patient. HRCT scans were performed using a standardized protocol, and images were interpreted by experienced radiologists. HRCT Protocol HRCT of the chest was performed using a multi-detector CT scanner. Imaging parameters included: • Thin-section axial images (1–1.25 mm slice thickness) • High spatial resolution reconstruction algorithm • Supine position during full inspiration • Additional expiratory images in selected cases HRCT Evaluation CT images were evaluated for the following features: • Ground-glass opacities (GGOs) • Reticulations • Honeycombing • Traction bronchiectasis • Subpleural bands • Fibrotic changes A scoring system was used to assess the severity and extent of lung involvement. Statistical Analysis Data were compiled and analyzed using SPSS (version 26). Descriptive statistics were used to summarize demographic and clinical characteristics. The prevalence and patterns of post-COVID interstitial lung disease on HRCT were calculated. Associations between clinical parameters and radiological findings were analyzed using appropriate statistical tests, with a p-value < 0.05 considered statistically significant. RESULTS AND OBSERVATIONS Pratibha Patil, et al. High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study. Int. J Med. Pharm. Res., 6 (5): 1529‐1536, 2025 1531 Table 1: Demographic Profile of Patients (n = 50) Parameter Value Age (Mean ± SD) 52.6 ± 13.4 years Age Range 28–78 years Gender - Male 34 (68%) - Female 16 (32%) Duration since COVID-19 6–20 weeks (mean: 10.2 weeks) History of Hospitalization 21 (42%) Oxygen Therapy during COVID-19 17 (34%) Table 2: Comorbidities in Post-COVID Patients (n = 50) Comorbidity No. of Patients Percentage (%) Diabetes Mellitus 18 36% Hypertension 15 30% Coronary Artery Disease 6 12% COPD 4 8% No Comorbidity 20 40% Fig; 1 Comorbidities in Post-COVID Patients (n = 50) Table 3: HRCT Findings in Post-COVID Patients (n = 50) HRCT Finding No. of Patients Percentage (%) Ground-glass opacities (GGO) 38 76% Interlobular septal thickening 29 58% Reticulations 22 44% Traction bronchiectasis 16 32% Subpleural bands 14 28% Honeycombing 5 10% Consolidation 6 12% Fibrotic changes (overall) 21 42% Pratibha Patil, et al. High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study. Int. J Med. Pharm. Res., 6 (5): 1529‐1536, 2025 1532 Fig; 2 HRCT Findings in Post-COVID Patients (n = 50) Table 4: Distribution of Fibrotic Changes by Severity Severity of Fibrosis No. of Patients Percentage (%) Mild (involving <25%) 9 18% Moderate (25–50%) 8 16% Severe (>50%) 4 8% Table 5: Association Between HRCT Fibrosis and Oxygen Requirement During COVID-19 (n = 50) Oxygen Therapy Fibrotic Changes Present Fibrotic Changes Absent Total Yes (n = 17) 13 (76.5%) 4 (23.5%) 17 No (n = 33) 8 (24.2%) 25 (75.8%) 33 Total 21 29 50 Chi-square test: p < 0.01 (statistically significant association between oxygen therapy and fibrosis development) Table 6: Duration Since COVID-19 and Fibrotic Changes on HRCT (n = 50) Duration Since Recovery Patients with Fibrosis Patients without Fibrosis Total Patients 4–8 weeks 4 (16%) 21 (84%) 25 9–12 weeks 8 (53.3%) 7 (46.7%) 15 >12 weeks 9 (60%) 6 (40%) 15 Chi-square test: p < 0.05 → Significant increase in fibrotic changes with time since recovery. Table 7: HRCT Score (Severity Index) in Post-COVID Patients HRCT Severity Score Range No. of Patients Percentage (%) 0–7 (Mild involvement) 19 38% 8–15 (Moderate) 21 42% >15 (Severe) 10 20% HRCT scoring was based on visual quantification of lobar involvement (total score out of 25). Table 8: Pattern of Lung Involvement on HRCT (Zonal Distribution) Zone Involved No. of Patients Percentage (%) Lower lobes 42 84% Middle lobes 28 56% Pratibha Patil, et al. High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study. Int. J Med. Pharm. Res., 6 (5): 1529‐1536, 2025 1533 Upper lobes 24 48% Diffuse involvement 14 28% Table 9: Comparison of HRCT Findings Based on Hospitalization Status HRCT Feature Hospitalized (n = 21) Non-hospitalized (n = 29) Ground-glass opacities 19 (90.5%) 19 (65.5%) Reticulations 14 (66.7%) 8 (27.6%) Fibrotic changes 15 (71.4%) 6 (20.7%) Traction bronchiectasis 11 (52.4%) 5 (17.2%) Honeycombing 4 (19%) 1 (3.4%) Significant differences in fibrotic changes and bronchiectasis were observed in hospitalized vs. non-hospitalized groups (p < 0.05) Table 10: Symptomatology and HRCT Correlation (n = 50) Presenting Symptom Patients (n) Fibrotic Changes Present Fibrotic Changes Absent Dyspnea (breathlessness) 38 20 18 Cough 31 15 16 Chest discomfort 18 9 9 Fatigue 12 5 7 56 year old male : HRCT – CHEST shows traction bronchiectasis and subpleural bands 78 year male: HRCT – CHEST shows traction bronchiectasis, ground-glass densities , reticulations and honey combing predominantly in bilateral lower lobes. Pratibha Patil, et al. High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study. Int. J Med. Pharm. Res., 6 (5): 1529‐1536, 2025 1534 72 year female: HRCT – CHEST shows traction bronchiectasis , interlobular septal thickening. ground-glass densities and reticulations 62 year male : HRCT – CHEST shows ill-defined ground-glass densities with reticulations 74 year male: HRCT – CHEST shows subpleural bands Pratibha Patil, et al. High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study. Int. J Med. Pharm. Res., 6 (5): 1529‐1536, 2025 1535 DISCUSSION In this cross-sectional study, HRCT evaluation of 50 post-COVID-19 patients presenting with persistent respiratory symptoms revealed that 42% had fibrotic lung changes. The most frequently observed HRCT patterns included groundglass opacities (76%), interlobular septal thickening (58%), and reticulations (44%). These results are in line with the study by Myall et al., who reported similar post-COVID fibrotic changes in up to 35% of hospitalized patients three months after infection [1]. The predominant involvement of the lower lobes (84%) and subpleural distribution observed in our study mirrors the anatomical predilection reported by Garg et al., who found peripheral and basal dominance in 82% of their post-COVID cohort [2]. Such distributions closely resemble organizing pneumonia and nonspecific interstitial pneumonia (NSIP)-like patterns, which are common post-viral sequelae [3]. Our analysis revealed a statistically significant association between oxygen therapy and the development of fibrosis (p < 0.01), with 76.5% of patients requiring oxygen showing fibrotic changes. This finding aligns with data from Huang et al., who found persistent lung abnormalities in patients with severe COVID-19 requiring oxygen, even at 6-month follow-up [4]. Similarly, Mo et al. reported reduced diffusion capacity and persistent radiological findings in 47% of severe COVID-19 survivors [5]. We also found a time-dependent increase in fibrotic changes, with 60% of patients scanned after 12 weeks postinfection demonstrating fibrosis compared to only 16% within 4–8 weeks. Yu et al. similarly documented progressive fibrotic evolution in thin-section CTs over time, reinforcing the concept that fibrotic remodeling may not be fully apparent in early convalescence [6]. The HRCT severity scoring in our study showed that 62% of patients had moderate to severe lung involvement, which is consistent with Pan et al., who observed higher scores in patients with severe acute disease and longer recovery durations [7]. In terms of clinical symptoms, dyspnea (76%) and cough (62%) were the most commonly reported complaints. Dyspnea showed the strongest association with fibrotic HRCT findings. This parallels findings by Bellan et al., who demonstrated that persistent respiratory symptoms are reliable clinical indicators of residual lung damage on imaging [8]. Moreover, hospitalized patients in our study had a significantly higher burden of fibrosis (71.4%) compared to nonhospitalized patients (20.7%). Chopra et al. and Han et al. reported similar associations, emphasizing that the severity of the initial illness correlates directly with the risk of post-COVID pulmonary fibrosis [9,10]. In contrast to some studies that suggest reversibility of early fibrotic-like changes [11], our data support the concern raised by Spagnolo et al. that persistent post-COVID fibrotic patterns may lead to irreversible interstitial lung disease, particularly in vulnerable individuals [12]. Our study adds to the growing body of evidence suggesting that HRCT is an essential tool in evaluating post-COVID lung sequelae. Early identification of fibrotic changes may aid in initiating pulmonary rehabilitation, optimizing followup care, and potentially selecting patients for anti-fibrotic therapy trials [13]. CONCLUSION This study highlights that a significant proportion (42%) of post-COVID-19 patients with persistent respiratory symptoms exhibit fibrotic interstitial lung changes on high-resolution computed tomography (HRCT). Ground-glass opacities, interlobular septal thickening, and reticulations were the most common HRCT findings. Fibrotic changes were significantly associated with prior oxygen therapy, hospitalization, and longer duration since COVID-19 recovery, indicating that disease severity and progression time are key contributors to post-infectious lung fibrosis. The lower lobes and peripheral zones were predominantly involved, and HRCT scoring helped quantify the extent of pulmonary involvement. Symptomatology, particularly dyspnea and cough, correlated well with imaging findings. Our results emphasize the crucial role of HRCT in early identification, monitoring, and management planning for postCOVID interstitial lung disease. Routine follow-up imaging may be warranted in symptomatic patients, especially those with severe acute illness or prolonged recovery. Further multicentric studies with larger sample sizes and functional correlation (e.g., spirometry) are recommended to guide long-term care strategies and assess the potential role of antifibrotic therapies. REFERENCES 1. Myall KJ, Mukherjee B, Castanheira AM, et al. Persistent post-COVID-19 interstitial lung disease: an observational study of corticosteroid treatment. Ann Am Thorac Soc. 2021;18(5):799–806. Pratibha Patil, et al. High-Resolution Ct In Diagnosing Interstitial Lung Disease In Post-Covid Patients: A Cross-Sectional Study. Int. J Med. Pharm. Res., 6 (5): 1529‐1536, 2025 1536 2. Garg M, Maralakunte M, Dhooria S, et al. Lung fibrosis after COVID-19 pneumonia. Indian J Radiol Imaging. 2021;31(Suppl 1):S152–S157. 3. George PM, Barratt SL, Condliffe R, et al. Respiratory follow-up of patients with COVID-19 pneumonia. Thorax. 2020;75(11):1009–1016. 4. Huang C, Huang L, Wang Y, et al. 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021;397(10270):220–232. 5. Mo X, Jian W, Su Z, et al. Abnormal pulmonary function in COVID-19 patients at time of hospital discharge. Eur Respir J. 2020;55(6):2001217. 6. Yu M, Liu Y, Xu D, et al. Prediction of the development of pulmonary fibrosis using serial thin-section CT and clinical features in patients discharged after treatment for COVID-19 pneumonia. Korean J Radiol. 2020;21(6):746– 755. 7. Pan Y, Guan H, Zhou S, et al. Initial CT findings and temporal changes in patients with the novel coronavirus pneumonia (2019-nCoV): a study of 63 patients in Wuhan, China. Eur Radiol. 2020;30(6):3306–3309. 8. Bellan M, Soddu D, Balbo PE, et al. Respiratory and psychophysical sequelae among patients with COVID-19 four months after hospital discharge. JAMA Netw Open. 2021;4(1):e2036142. 9. Chopra V, Flanders SA, O'Malley M, et al. Sixty-day outcomes among patients hospitalized with COVID-19. Ann Intern Med. 2021;174(4):576–578. 10. Han X, Fan Y, Alwalid O, et al. Six-month follow-up chest CT findings after severe COVID-19 pneumonia. Radiology. 2021;299(1):E177–E186. 11. Carfi A, Bernabei R, Landi F. Persistent symptoms in patients after acute COVID-19. JAMA. 2020;324(6):603–605. 12. Spagnolo P, Balestro E, Aliberti S, et al. Pulmonary fibrosis secondary to COVID-19: a call to arms? Lancet Respir Med. 2020;8(8):750–752. 13. George PM, Wells AU, Jenkins RG. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy. Lancet Respir Med. 2020;8(8):807–815.